Cancer therapies that harness the immune system don’t work for all patients. Verseau Therapeutics aims to bring cancer immunotherapy to more people by targeting a type of immune cell present in the vast majority of tumors and directing it to fight the disease.

Verseau launched Monday backed by $50 million in financing. The Bedford, MA-based company says it will use the cash to advance its experimental cancer immunotherapies toward clinical testing.

Immunotherapies that enlist T cells, the frontline defenders of the immune system, show clinical benefit in approximately 25 percent of cancers, according to Verseau. Rather than targeting T cells, Verseau… Read more »